Biohealth Innovation

Click here to view original article »

Trouble Viewing This Email: Click Here

June 1, 2022

FOUNDING MEMBER OF

United Therapeutics Announces FDA Approval of Tyvaso DPI™ | United Therapeutics Corporation

First approval of a dry powder inhaler for treatment of PAH and PH-ILD

DPI device represents a convenient option for administration of treprostinil therapy

Commercial launch activities underway; patient availability expected in June 2022

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD.

CAR T-cell Therapy Continues to Show Promise for Myasthenia Gravis

Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five patients with generalized myasthenia gravis (gMG) enrolled in a Phase 1b/2a clinical trial.

“I am very encouraged by the interim analysis findings,” as the therapy “appears safe and well tolerated, and the extent of clinical improvement seen in our early participants is remarkable,” Volkan Granit, MD, the trial’s principal investigator at the University of Miami, said in a press release.

George Mason Biotech Startup Virongy Continues to Expand in Northern Virginia

After making striking advancements in HIV and COVID-19 research, Virongy, a biotechnology company in Prince William County, Virginia, has set its sight on tackling even more viruses. With millions of people being afflicted by viral illnesses worldwide each year, Virongy’s objective addresses an ever-increasing market need.

“Our goal is to create advanced diagnostics so that doctors can promptly prescribe treatments to patients,” said Brian Hetrick, chief scientific officer of Virongy.

How can your BioHealth business benefit from a review by BHI industry experts? Please register for our next Entrepreneur-In-Residence (EIR) day on June 20th and find out. To sign-up for any of the EIR dates in 2022, please follow this link.

These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.

To sign-up for any of the EIR dates in 2022, please follow this link.

TEDCO to Receive up to $50 Million from State Small Business Credit Initiative · BioBuzz

COLUMBIA, Md. (May 25, 2022)—TEDCO, Maryland’s economic engine for technology companies, announced today it will receive up to $50 million from Governor Hogan’s small business relief plan that was approved for funding from the United States Treasury Department’s State Small Business Credit Initiative (SSBCI). TEDCO will allocate the funds into four existing programs targeting technology-based Maryland businesses and entrepreneurs.

“We want to express our thanks to our colleagues at DHCD for their leadership on getting us to this point,” said TEDCO CEO Troy LeMaile-Stovall. “And this point is about investing in individuals and communities that are underrepresented in our innovation ecosystem, while also creating additional funds for TEDCO to invest in firms that will start and scale in Maryland – generating a more equitable future.”

HHS Secretary Becerra Establishes ARPA-H within NIH, Names Adam H. Russell, D.Phil. Acting Deputy Director | HHS.gov

Health and Human Services Secretary Xavier Becerra today announced the formal establishment of the Advanced Research Project Agency for Health (ARPA-H) as an independent entity within the National Institutes of Health and the appointment of Adam H. Russell, D.Phil., as acting deputy director. Currently, Dr. Russell is the Chief Scientist at University of Maryland's Applied Research Laboratory for Intelligence and Security (ARLIS). He spent more than a decade as a Program Manager, first at the Intelligence Advanced Research Projects Activity (IARPA) and then at the Defense Advanced Research Projects Agency (DARPA). Dr. Russell will begin his new role in June.

Save Ukrainian Lives: Provide Access to Blood by FINCA International

Hemafuse is the Solution

There is an urgent need for blood in Ukraine. With donor blood in short supply, Hemafuse can meet this need. It is a simple, handheld device that enables surgeons to capture and reuse a trauma patient's own blood. Hemafuse is completely mechanical and can be used regardless of infrastructure. For more information visit Sisu Global's website.

Image: https://fundrazr.com

U.S. Treasury awards first round of funding for State Small Business Credit Initiative - Financial Regulation News

The U.S. Department of the Treasury awarded the first batch of funding awards for the State Small Business Credit Initiative (SSBCI), a program designed to increase access to capital for traditionally underserved small businesses and entrepreneurs.

The new, expanded SSBCI provides nearly $10 billion to states, the District of Columbia, territories, and Tribal governments to promote entrepreneurship, especially in traditionally underserved communities. SSBCI funding is expected to catalyze up to $10 of private investment for every $1 of SSBCI capital funding. State governments filed plans with the Treasury on using their SSBCI allocation to provide funding to small businesses.

Which SARS-CoV-2 Variant Will Cause the Next Wave? An AI Tool Predicts

First, there was Delta. Then Omicron. Now, it’s the Omicron subvariant BA.2.12.1. And, public health officials are keeping a close watch on the BA.4 and BA.5 subvariants. These waves of cases, caused by infections with new variants, have characterized the COVID-19 pandemic. But how can public health officials know which variants are likely to cause large numbers of cases and which will not take hold in the population?

Legal & General Capital makes first U.S. investment, with seed capital for $4Bn platform to fund major life-science and technology assets across multiple regional U.S. markets | News Direct

Legal & General Capital and U.S.-based real estate developer Ancora establish landmark 50:50 partnership as LGC internationalizes its platform to drive shareholder value

London, England, UK and Durham, NC | May 25, 2022 08:00 AM Eastern Daylight Time

Legal & General Capital (LGC) today announced that it has formed a 50:50 partnership with U.S.-based real estate developer Ancora to create a real estate platform dedicated to driving life science, research and technology growth across the U.S. The deal will see Legal & General Capital investing an initial $500 million of seed capital to form a new company, Ancora L&G, LLC. Operating under the name Ancora, the business’ geographic focus will sit predominantly within emerging regional markets in the U.S. where early mover advantages are available.

These Are The Leading And Lagging States For Female-Founded Startups

Female-founded companies account for less than one-fourth of venture funding recipients in every U.S. state with a startup scene. But they’re a lot closer to the top of the spectrum in some states, and much nearer to the bottom in others.

That was the finding from a state-by-state analysis of funding over the past three years to companies with at least one female founder. We focused on 25 states that collectively account for over 95 percent of total U.S. funding rounds.

Image: https://news.crunchbase.com

TEDCO’s Strategic Plan Sets Bold Path for the Future | TEDCO

TEDCO’s strategic plan, The Time, Talent, and Treasure Imperative for Maryland’s Ecosystem (T3IME), seizes this moment to build upon past successes and move forward differently than we have in the past. Specifically, we must scale significantly, and expand the type of resources over the next ten years (FY23-FY33). We must ensure that in this growth, we expand and include those that have been historically excluded. We will achieve this not only with market-based fiscal returns but also by curating, investing, and growing to scale enterprises that drive societal change for our citizens and the world.

Image: https://www.tedcomd.com

Home - Quantum World Congress (Nov 29 - Dec 1)

Quantum World Congress is the first-ever gathering of its kind – connecting the world’s quantum ecosystem, including the brightest researchers, innovators, technology developers, legislators, and industry experts – to accelerate the value of the growing quantum industry.

Advancing and Commercializing Longevity Market Innovations — Leveraging Seed Funding, Foundational, and Accelerator Support To Advance Innovations for Older Adults - BIO International Convention | BIO

1:45 PM - 2:45 PM (PDT), Wednesday, June 15, 2022 ・ Upper Level, Session Room 6D

Longevity tech is one of the fastest-growing yet relatively underserved markets worldwide. Forty percent of today’s older adults self-identify as early adopters of new technology, making the field ripe for innovation. To meet the needs of older consumers, we must understand their needs and behaviors, develop strategies designed to target them, and provide capital to seed technological innovations. Non-profit foundations and accelerators, such as AARP and its Innovation Labs, play a critical role helping entrepreneurs understand, optimize, and test longevity innovations

Viewport Window × × ×